Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 May, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Brooks Laboratories Ltd

About the Company - Brooks Laboratories Ltd

Brooks Laboratories Ltd. is a Public Limited Listed company incorporated on 23/01/2002 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24232HP2002PLC000267 and registration number is 000267. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 76.97 Cr. and Equity Capital is Rs. 24.70 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsUnit 1: Village Kishanpura,. Solan District Himachal Pradesh 174101investors@brookslabs.net
http://www.brookslabs.net
Management
NamePosition Held
Ms. Sonia GuptaIndependent Director
Mr. Deepak MahajanIndependent Director
Mr. Rajnish Kumar BediIndependent Director
Mr. Jitendra Pratap SinghWhole Time Director
Mr. Durga Shankar MaityAdditional Director
Mr. Bhushan Singh RanaAdditional Director

Basic Stock Data of Brooks Laboratories Ltd

Last Updated: May 13, 2024, 12:28 pm

Market Cap 257 Cr.
Current Price 98.5
High / Low186/56.5
Stock P/E
Book Value 30.1
Dividend Yield0.00 %
ROCE27.7 %
ROE23.4 %
Face Value 10.0
PEG Ratio0.00

Competitors of Brooks Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Amerise Biosciences Ltd 4.10 Cr. 0.620.93/0.54 0.810.00 %2.73 %2.75 % 1.00
Glenmark Pharmaceuticals Ltd 29,006 Cr. 1,0281,098/587234 3310.24 %14.2 %5.44 % 1.00
Alembic Ltd 2,463 Cr. 95.9108/59.29.67 82.52.24 %4.18 %8.67 % 2.00
Alembic Pharmaceuticals Ltd 19,751 Cr. 1,0051,094/50033.4 2270.77 %7.40 %7.20 % 2.00
Bafna Pharmaceuticals Ltd 209 Cr. 88.5126/75.918.6 34.80.00 %15.9 %16.4 % 10.0
Industry Average10,286.62 Cr443.6059.13135.220.65%8.88%8.09%3.20

Brooks Laboratories Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales29.2420.9214.6221.7021.4619.0128.4617.1218.0815.3012.6115.7024.32
Expenses23.8921.5719.1222.0725.7425.3932.3725.7227.3023.8516.3119.6125.42
Operating Profit5.35-0.65-4.50-0.37-4.28-6.38-3.91-8.60-9.22-8.55-3.70-3.91-1.10
OPM %18.30%-3.11%-30.78%-1.71%-19.94%-33.56%-13.74%-50.23%-51.00%-55.88%-29.34%-24.90%-4.52%
Other Income0.520.600.060.830.110.370.180.030.400.450.020.050.09
Interest0.800.780.740.760.750.740.840.620.630.750.180.170.19
Depreciation1.711.721.741.781.741.881.951.982.282.330.440.440.44
Profit before tax3.36-2.55-6.92-2.08-6.66-8.63-6.52-11.17-11.73-11.18-4.30-4.47-1.64
Tax %0.00%0.00%-150.00%45.19%27.33%14.25%8.90%15.85%32.82%15.21%0.00%0.00%0.00%
Net Profit3.37-2.56-17.30-1.14-4.83-7.40-5.93-9.40-7.87-9.48-4.30-4.47-1.64
EPS in Rs1.29-0.98-6.60-0.44-1.84-2.52-1.37-2.63-1.79-1.92-1.64-1.71-0.62

Brooks Laboratories Ltd Quarterly Chart

Brooks Laboratories Ltd Profit & Loss

MonthMar 2021Mar 2022Mar 2023TTM
Sales77916368
Expenses771059085
Operating Profit1-14-26-17
OPM %1%-16%-42%-25%
Other Income11-31
Interest3321
Depreciation7774
Profit before tax-9-24-38-22
Tax %-115%19%19%
Net Profit-19-19-31-20
EPS in Rs-7.40-4.31-7.98-5.89
Dividend Payout %0%0%0%

Brooks Laboratories Ltd Profit & Loss Yearly Chart

Brooks Laboratories Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:1%
TTM:26%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:0%
TTM:-4%
Stock Price CAGR
10 Years:16%
5 Years:14%
3 Years:-5%
1 Year:49%
Return on Equity
10 Years:%
5 Years:%
3 Years:-21%
Last Year:-28%

Last Updated: May 13, 2024, 12:28 pm

Brooks Laboratories Ltd Balance Sheet

MonthMar 2021Mar 2022Mar 2023Sep 2023
Equity Capital25252525
Reserves54634953
Borrowings312574
Other Liabilities52832923
Total Liabilities162196110106
Fixed Assets1081101514
CWIP11500
Investments006458
Other Assets54713134
Total Assets162196110106

Brooks Laboratories Ltd Reserves and Borrowings Chart

Brooks Laboratories Ltd Cash Flow

MonthMar 2021Mar 2022Mar 2023
Cash from Operating Activity 4-37-14
Cash from Investing Activity -5-250
Cash from Financing Activity 16411
Net Cash Flow02-3

Brooks Laboratories Ltd Financial Efficiency Indicators

MonthMar 2021Mar 2022Mar 2023
Debtor Days657174
Inventory Days17815780
Days Payable233159165
Cash Conversion Cycle968-12
Working Capital Days-595-3
ROCE %-16%-28%

Brooks Laboratories Ltd Financial Efficiency Indicators Chart

Brooks Laboratories Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters66.41%66.41%66.41%66.41%66.41%66.41%66.41%66.41%66.41%63.59%63.59%63.59%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.46%3.86%3.86%
Public33.59%33.59%33.59%33.59%33.59%33.58%33.59%33.59%33.58%33.94%32.56%32.55%
No. of Shareholders10,42910,37910,91611,14511,10410,52410,41010,70911,21610,68610,02811,432

Brooks Laboratories Ltd Shareholding Pattern Chart

No. of Brooks Laboratories Ltd Shareholders

Brooks Laboratories Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Quant Business Cycle Fund5289370.846.69
Quant Healthcare Fund2767081.993.5
Quant Small Cap Fund1873460.022.37

Brooks Laboratories Ltd ROCE Trend

Brooks Laboratories Ltd EPS Trend

Brooks Laboratories Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21
FaceValue10.0010.0010.00
Basic EPS (Rs.)-12.57-7.82-7.84
Diluted EPS (Rs.)-12.57-7.82-7.84
Cash EPS (Rs.)-8.39-4.84-4.95
Book Value[Excl.RevalReserv]/Share (Rs.)29.9454.3732.04
Book Value[Incl.RevalReserv]/Share (Rs.)29.9454.3732.04
Revenue From Operations / Share (Rs.)25.5936.8731.27
PBDIT / Share (Rs.)-10.61-5.440.50
PBIT / Share (Rs.)-13.46-8.42-2.38
PBT / Share (Rs.)-14.20-9.67-3.64
Net Profit / Share (Rs.)-11.23-7.82-7.84
NP After MI And SOA / Share (Rs.)-8.46-6.55-7.84
PBDIT Margin (%)-41.47-14.761.62
PBIT Margin (%)-52.59-22.83-7.62
PBT Margin (%)-55.48-26.23-11.63
Net Profit Margin (%)-43.89-21.20-25.07
NP After MI And SOA Margin (%)-33.06-17.77-25.08
Return on Networth / Equity (%)-28.26-25.67-24.47
Return on Capital Employeed (%)-43.41-14.14-5.98
Return On Assets (%)-19.06-8.26-11.95
Long Term Debt / Equity (X)0.000.140.18
Total Debt / Equity (X)0.070.380.35
Asset Turnover Ratio (%)0.410.570.00
Current Ratio (X)0.831.250.78
Quick Ratio (X)0.490.680.41
Inventory Turnover Ratio (X)2.142.310.00
Interest Coverage Ratio (X)-12.01-4.340.40
Interest Coverage Ratio (Post Tax) (X)-11.87-5.24-5.25
Enterprise Value (Cr.)159.23271.01179.90
EV / Net Operating Revenue (X)2.522.982.33
EV / EBITDA (X)-6.07-20.15143.19
MarketCap / Net Operating Revenue (X)2.451.971.99
Price / BV (X)2.092.841.94
Price / Net Operating Revenue (X)2.451.971.99
EarningsYield-0.13-0.09-0.12

Brooks Laboratories Ltd Profitability Ratios (%)

Brooks Laboratories Ltd Liquidity Ratios

Brooks Laboratories Ltd Liquidity Ratios (%)

Brooks Laboratories Ltd Interest Coverage Ratios (%)

Brooks Laboratories Ltd Valuation Ratios

Fair Value

Fair Value: ₹107.76

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 9.41% compared to the current price ₹98.5

Default values used*: Deafault value of 15 for Stock P/E is used

Intrinsic Value: ₹135.64

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 37.71% compared to the current price ₹98.5

Default values used*: Deafault value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: 25.87%

*Investments are subject to market risks

Strength and Weakness of Brooks Laboratories Ltd Stock

StrengthWeakness
  1. The stock has a low average Working Capital Days of 29.00, which is a positive sign.
  2. The company has higher reserves (54.75 cr) compared to borrowings (16.75 cr), indicating strong financial stability.
  1. The stock has a low average ROCE of -14.67%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 21.67, which may not be favorable.
  3. The company has not shown consistent growth in sales (74.75) and profit (-23.25).

FAQ

What is the latest fair value of Brooks Laboratories Ltd?

The latest fair value of Brooks Laboratories Ltd is ₹107.76.

What is the Market Cap of Brooks Laboratories Ltd?

The Market Cap of Brooks Laboratories Ltd is 257 Cr..

What is the current Stock Price of Brooks Laboratories Ltd as on 29 May 2024?

The current stock price of Brooks Laboratories Ltd as on 29 May 2024 is ₹98.5.

What is the High / Low of Brooks Laboratories Ltd stocks in FY 2024?

In FY 2024, the High / Low of Brooks Laboratories Ltd stocks is 186/56.5.

What is the Stock P/E of Brooks Laboratories Ltd?

The Stock P/E of Brooks Laboratories Ltd is .

What is the Book Value of Brooks Laboratories Ltd?

The Book Value of Brooks Laboratories Ltd is 30.1.

What is the Dividend Yield of Brooks Laboratories Ltd?

The Dividend Yield of Brooks Laboratories Ltd is 0.00 %.

What is the ROCE of Brooks Laboratories Ltd?

The ROCE of Brooks Laboratories Ltd is 27.7 %.

What is the ROE of Brooks Laboratories Ltd?

The ROE of Brooks Laboratories Ltd is 23.4 %.

What is the Face Value of Brooks Laboratories Ltd?

The Face Value of Brooks Laboratories Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Brooks Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE